Demonstration of durable hepatitis B immune memory in children vaccinated with a DTaP5-IPV-HepB-Hib infant-toddler series 7 to 8 years previously

References

• World Health Organization. Global hepatitis report, 2017. 2017 [accessed 2021 May 25]. http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1.
   Google Scholar
• Schillie S, Vellozzi C, Reingold A, Harris A, Haber P, Ward JW, Nelson NP. Prevention of hepatitis B virus infection in the United States: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep. 2018;67(1):1–7. doi:10.15585/mmwr.rr6701a1.
   PubMed Web of Science ®Google Scholar
• Whitford K, Liu B, Micallef J, Yin JK, Macartney K, Van Damme P, Kaldor JM. Long-Term impact of infant immunization on hepatitis B prevalence: a systematic review and meta-analysis. Bull World Health Organ. 2018;96(7):484–97. doi:10.2471/BLT.17.205153.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Hepatitis B vaccines: WHO position paper – July 2017. 2017 [accessed 2021 May 10]. https://apps.who.int/iris/bitstream/handle/10665/255841/WER9227.pdf;jsessionid=6475C9E555C20312F6326A7E2B3ED1DD?sequence=1.
   Google Scholar
• Immunization Practices Advisory Committee. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep. 1991;40(RR–13):1–25.
   Google Scholar
• Van Damme P, Ward JW, Shouval D, Zanetti A. Hepatitis B vaccines. In: Plotlin S; Offit P; Orenstein W, and Edwards K, editors. Plotkin’s vaccines. Philadelphia (PA): Elsevier; 2018. p. 342–74.
   Google Scholar
• Bruce MG, Bruden D, Hurlburt D, Zanis C, Thompson G, Rea L, Toomey M, Townshend-Bulson L, Rudolph K, Bulkow L, et al. Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow-up study and response to a booster dose. J Infect Dis. 2016;214(1):16–22. doi:10.1093/infdis/jiv748.
   PubMed Web of Science ®Google Scholar
• Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine. 2000;19(7–8):877–85. doi:10.1016/S0264-410X(00)00224-3.
   PubMed Web of Science ®Google Scholar
• Kosalaraksa P, Chokephaibulkit K, Benjaponpitak S, Pancharoen C, Chuenkitmongkol S, B’-Chir S, Da Costa X, Vidor E. Persistence of hepatitis B immune memory until 9-10 years of age following hepatitis B vaccination at birth and DTaP-IPV-HB-PRP∼T vaccination at 2, 4 and 6 months. Hum Vaccin Immunother. 2018;14(5):1257–65. doi:10.1080/21645515.2018.1426418.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Dionne M, Leroux-Roels G, Van Der Meeren O, Di Paolo E, Salaun B, Surya Kiran P, Folschweiller N. Persistence of HBsAg-specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults. J Viral Hepat. 2019;26(9):1066–75. doi:10.1111/jvh.13125.
   PubMed Web of Science ®Google Scholar
• Poorolajal J, Mahmoodi M, Majdzadeh R, Nasseri-Moghaddam S, Haghdoost A, Fotouhi A. Long-Term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis. Vaccine. 2010;28(3):623–31. doi:10.1016/j.vaccine.2009.10.068.
   PubMed Web of Science ®Google Scholar
• Cassidy WM, Watson B, Ioli VA, Williams K, Bird S, West DJ. A randomized trial of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: antibody responses, safety, and immunologic memory. Pediatrics. 2001;107(4):626–31. doi:10.1542/peds.107.4.626.
   PubMed Web of Science ®Google Scholar
• Diez-Domingo J, Flores SA, Martin JC, Klopfer SO, Schödel FP, Bhuyan PK. A randomized, multicenter, open-label clinical trial to assess the anamnestic immune response 4 to 8 years after a primary hepatitis B vaccination series. Pediatr Infect Dis J. 2010;29:972–74.
   PubMed Web of Science ®Google Scholar
• United States Food & Drug Administration. VAXELIS™ [prescribing information]. Swiftwater (PA): MSP Vaccine Company; 2020 [accessed 2022 May 10]. https://www.fda.gov/vaccines-blood-biologics/vaxelis.
   Google Scholar
• European Medicines Agency. VAXELIS™ [summary of product characteristics]. Leiden (The Netherlands): MCM Vaccine B.V; 2020 [accessed 2022 May 10].https://www.ema.europa.eu/en/medicines/human/EPAR/vaxelis.
   Google Scholar
• Merck & Co., Inc. Merck and Sanofi’s first and only six-in-one pediatric combination vaccine now available in the United States. 2021 [accessed 2022 January 5]. https://www.merck.com/news/merck-and-sanofis-first-and-only-six-in-one-pediatric-combination-vaccine-now-available-in-the-united-states/.
   Google Scholar
• Knuf M, Haas H, Garcia-Corbeira P, Turriani E, Mukherjee P, Janssens W, Berlaimont V. Hexavalent vaccines: what can we learn from head-to-head studies? Vaccine. 2021;39(41):6025–36. doi:10.1016/j.vaccine.2021.08.086.
   PubMed Web of Science ®Google Scholar
• Silfverdal SA, Icardi G, Vesikari T, Flores SA, Pagnoni MF, Xu J, Liu GF, Stek JE, Boisnard F, Thomas S, et al. A phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11-12 months. Vaccine. 2016;34(33):3810–16. doi:10.1016/j.vaccine.2016.05.054.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Becker T, Vertruyen AF, Poschet K, Flores SA, Pagnoni MF, Xu J, Liu GF, Stek JE, Boisnard F, et al. A phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at two, three, four and twelve months. Pediatr Infect Dis J. 2017;36(2):209–15. doi:10.1097/INF.0000000000001406.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Xu J, Johnson DR, Hall J, Marček T, Goveia MG, Acosta CJ, Lee AW. Hepatitis B and pertussis antibodies in 4- to 5-year-old children previously vaccinated with different hexavalent vaccines. Hum Vaccin Immunother. 2020;16(4):867–74. doi:10.1080/21645515.2019.1673119.
   PubMed Web of Science ®Google Scholar
• Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26(4):404–13. doi:10.1093/biomet/26.4.404.
   Google Scholar
• Collett D, Stepniewska K. Some practical issues in binary data analysis. Stat Med. 1999;18(17–18):2209–21. doi:10.1002/(SICI)1097-0258(19990915/30)18:17/18<2209:AID-SIM250>3.0.CO;2-U.
   PubMed Web of Science ®Google Scholar
• Reed GF, Meade BD, Steinhoff MC. The reverse cumulative distribution plot: a graphic method for exploratory analysis of antibody data. Pediatrics. 1995;96(3 Pt 2):600–03. doi:10.1542/peds.96.3.600.
   PubMed Web of Science ®Google Scholar
• Sharma R, Ahlm C, Ostergaard L, Dowell A, Tran C, Thomas S, Eymin C. Persistence of immunity in healthy adults aged ≥ 50 years primed with a hepatitis B vaccine 3 years previously. Hum Vaccin Immunother. 2015;11(7):1709–16. doi:10.1080/21645515.2015.1019187.
   PubMed Web of Science ®Google Scholar
• Behre U, Van Der Meeren O, Crasta P, Hanssens L, Mesaros N. Lasting immune memory against hepatitis B in 12-13-year-old adolescents previously vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy. Hum Vaccin Immunother. 2016;12(11):2916–20. doi:10.1080/21645515.2016.1202388.
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Behre U, Adelt T, Donner M, Suryakiran PV, Janssens W, Mesaros N, Panzer F. Long-Term antibody persistence against hepatitis B in adolescents 14-15-years of age vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy. Hum Vaccin Immunother. 2019;15(1):235–41. doi:10.1080/21645515.2018.1509658.
   PubMed Web of Science ®Google Scholar
• Steiner M, Ramakrishnan G, Gartner B, Van Der Meeren O, Jacquet JM, Schuster V. Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV/Hib in the first and 2nd year of life. BMC Infect Dis. 2010;10:9. doi:10.1186/1471-2334-10-9.
   PubMed Web of Science ®Google Scholar
• Van Der Meeren O, Bleckmann G, Crasta PD. Immune memory to hepatitis B persists in children aged 7-8 years, who were vaccinated in infancy with 4 doses of hexavalent DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine. Hum Vaccin Immunother. 2014;10(6):1682–87. doi:10.4161/hv.28480.
   PubMed Web of Science ®Google Scholar
• Simons BC, Spradling PR, Bruden DJ, Zanis C, Case S, Choromanski TL, Apodaca M, Brogdon HD, Dwyer G, Snowball M, et al. A longitudinal hepatitis B vaccine cohort demonstrates long-lasting hepatitis B virus (HBV) cellular immunity despite loss of antibody against HBV surface antigen. J Infect Dis. 2016;214(2):273–80. doi:10.1093/infdis/jiw142.
   PubMed Web of Science ®Google Scholar
• Zinkernagel RM, Bachmann MF, Kündig TM, Oehen S, Pirchet H, Hengartner H. On immunological memory. Annu Rev Immunol. 1996;14:333–67. doi:10.1146/annurev.immunol.14.1.333.
   PubMed Web of Science ®Google Scholar
• Karvonen T, Auranen K, Kuusi M, Leino T. Epidemiology of hepatitis B infection in Finland: implications for immunisation policy. Vaccine. 2017;35(3):412–18. doi:10.1016/j.vaccine.2016.11.090.
   PubMed Web of Science ®Google Scholar